NEW DELHI: The Drugs Controller of India is intensifying its regulatory surveillance against the illegal sale and promotion of weight loss drugs (GLP-1), the Ministry of Health and Family Welfare said on Tuesday.According to the ministry, the move aims to ensure ethical pharmaceutical practices across the drug supply chain.”With the recent introduction of multiple generic variants of GLP-1-based weight loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks,” the ministry said in an official statement.Israel Iran WarUS-Israel-Iran War News Live Updates: Israel says more missiles launched from Iran; Kuwait claims drone attacks by TehranTrump Talks Iran Deal Window: US president sees major points of agreement; five day period to test talks’Fake news’: Iranian Speaker says Trump’s talk claims aimed at manipulating oil markets”Taking cognisance of the situation, India’s Drugs Controller, in collaboration with state regulators, has initiated a series of targeted actions to curb possible malpractices across the pharmaceutical supply chain and prevent unauthorized sales and use,” it added.The ministry recalled that on March 10, a comprehensive advisory was issued to all manufacturers, explicitly prohibiting surrogate advertisements and any form of indirect promotion that could mislead consumers or encourage off-label usage.The statement further noted that enforcement activities have been significantly scaled up in recent weeks, with audits and inspections conducted at 49 entities across multiple regions. These included online pharmacy warehouses, drug wholesalers, retailers, and wellness and slimming clinics.”The misuse of weight loss drugs without clinical oversight can lead to severe health complications. Citizens are advised to use such medications only under the guidance of qualified medical practitioners,” the health ministry stated.The drug has been approved in India with the condition that it be prescribed only by endocrinologists and internal medicine specialists, and for certain indications, by cardiologists.About the AuthorTOI News DeskThe TOI News Desk comprises a dedicated and tireless team of journalists who operate around the clock to deliver the most current and comprehensive news and updates to the readers of The Times of India worldwide. With an unwavering commitment to excellence in journalism, our team is at the forefront of gathering, verifying, and presenting breaking news, in-depth analysis, and insightful reports on a wide range of topics. The TOI News Desk is your trusted source for staying informed and connected to the ever-evolving global landscape, ensuring that our readers are equipped with the latest developments that matter most.”Read MoreEnd of ArticleFollow Us On Social MediaVideosIndia Issues RFI for Engine Test Complex, Facility To End India’s Foreign Engine Testing DependencyIndia, US Hold Talks As West Asia Crisis Raises Energy ConcernsTwo More Indian LPG Ships Pine Gas And Jag Vasant Transit Strait Of Hormuz Amid Iran-Israel War’India Moving Ahead With Resolve’: PM Modi’s Big Message On West Asia Conflict’Never Faced Such Humiliation’: Jaya Bachchan Slams VIP Culture In RS, Flags Traffic DisruptionsUS Finally Ready For De-Escalation? Iran Says Trump’s Threat To Blow Up Its Power Grid Was ‘Bluff’’100% Under Control Of Trump’: Rahul Gandhi Slams PM Modi Over West Asia Remarks In Lok Sabha’India Should Put House In Order First: Gita Gopinath’s Big Warning To Modi Govt Amid Iran WarIndia’s Nuclear Submarine Trio Is What China and Pakistan Should Pay Attention ToQawwali Meets Politics: LJP MP Shambhavi Chaudhary’s Dhurandhar Dig Targets Opposition In Lok Sabha123Photostories6 iconic destinations on the banks of the world’s longest riverStep inside Adar and Natasha Poonawalla’s Rs.750 crore elegant Pune farmhouseHarbhajan Singh and Geeta Basra’s ₹7 crore bungalow in Jalandhar, Punjab is a personalised sanctuary rooted in cricket, memories and family values5 things you probably didn’t know about the world’s highest national parkBaby girl names inspired by color red6 high-protein breakfast dishes made with paneer10 house names inspired by the sky, stars, and cosmos, with their meanings8 plants you only need to grow once for endless harvestsMost people get this wrong about BP checks: Here’s what a doctor saysWorld’s deadliest rat that can kill an elephant, and 8 other weird rodents that break every rule of nature123Hot PicksTrump Iran DealMohammad Bagher GhalibafSan Francisco AirportGold rate todayIncome Tax CalculatorPublic holidays March 2026Bank Holidays MarchTop TrendingGolden state warriors vs dallas mavericks injury reportPatrick MahomesJoe MazzullaColombian Military Plane CrashBrittany MahomesWWE Raw News RoundupSilver Rate TodayPahalgam hotel caseTrump Iran DealBihar Board Science Topper
NEW DELHI: The Drugs Controller of India is intensifying its regulatory surveillance against the illegal sale and promotion of weight loss drugs (GLP-1), the Ministry of Health and Family Welfare said on Tuesday.According to the ministry, the move aims to ensure ethical pharmaceutical practices across the drug supply chain.“With the recent introduction of multiple generic variants of GLP-1-based weight loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks,” the ministry said in an official statement.“Taking cognisance of the situation, India’s Drugs Controller, in collaboration with state regulators, has initiated a series of targeted actions to curb possible malpractices across the pharmaceutical supply chain and prevent unauthorized sales and use,” it added.The ministry recalled that on March 10, a comprehensive advisory was issued to all manufacturers, explicitly prohibiting surrogate advertisements and any form of indirect promotion that could mislead consumers or encourage off-label usage.The statement further noted that enforcement activities have been significantly scaled up in recent weeks, with audits and inspections conducted at 49 entities across multiple regions. These included online pharmacy warehouses, drug wholesalers, retailers, and wellness and slimming clinics.“The misuse of weight loss drugs without clinical oversight can lead to severe health complications. Citizens are advised to use such medications only under the guidance of qualified medical practitioners,” the health ministry stated.The drug has been approved in India with the condition that it be prescribed only by endocrinologists and internal medicine specialists, and for certain indications, by cardiologists.